Keywords: lynx, solexa, acquire, dna, technology, assets, therapeutics

Lynx and Solexa acquire DNA technology assets

Article | 5 April 2004

Lynx Therapeutics of the USA and UK-based Solexa have announced the joint acquisition from Switzerland-based Manteia SA of the rights to proprietary technology assets for DNA colony generation.

Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.

FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!

Sign up in less than 60 seconds...no payment needed

Want to read the full article?
Take a 30 day FREE Trial worth £60

Take a no obligations 30 day trial.
Only one trial per user. Find out more details

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in